Wathén Katja-Anneli, Tuutti Eija, Stenman Ulf-Håkan, Alfthan Henrik, Halmesmäki Erja, Finne Patrik, Ylikorkala Olavi, Vuorela Piia
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Biomedicum Helsinki, 00029 HUS, Helsinki, Finland.
J Clin Endocrinol Metab. 2006 Jan;91(1):180-4. doi: 10.1210/jc.2005-1076. Epub 2005 Nov 1.
Vascular endothelial growth factor (VEGF) promotes placental vascularization, which is inadequate in preeclampsia and intrauterine growth retardation (IUGR). The soluble receptor of VEGF (sVEGFR-1), also known as soluble fms-like tyrosine kinase-1, is produced in the placenta and reduces VEGF activity. Therefore, elevated sVEGFR-1 could contribute to the development of preeclampsia and IUGR.
The objective of this study was to study maternal serum sVEGFR-1 concentration in early pregnancy ending in preeclampsia and IUGR.
This was a case-control study.
This study was conducted at Helsinki University Central Hospital (Helsinki, Finland), a tertiary referral center.
Patients included 124 pregnant women, of whom 49 developed preeclampsia, 16 gave birth to IUGR infants without preeclampsia, and 59 remained normotensive and gave birth to normal-sized infants. Serum samples were collected at 12-15 and 16-20 gestational weeks.
Serum sVEGFR-1 concentrations were determined by ELISA.
Women with subsequent preeclampsia had higher [median; interquartile range (IQR)] concentrations of sVEGFR-1 at 16-20 wk gestation (436 and 282-699 ng/liter; P = 0.005) than the controls (296 and 184-508 ng/liter). The conclusion was the same if women with mild (340 and 285-750 ng/liter; P = 0.043) or severe (497 and 235-699 ng/liter; P = 0.022) preeclampsia were analyzed separately. An elevated sVEGFR-1 concentration at 16-20 wk gestation is associated with an increased risk of preeclampsia but not of isolated IUGR. Soluble VEGFR-1 concentration decreased by 15% from the first to the second sampling in the controls but not in women with preeclampsia or IUGR.
Elevated sVEGFR-1 concentrations at 16-20 wk gestation precede the clinical manifestations of preeclampsia. By neutralizing VEGF, sVEGFR-1 may contribute to inadequate placental vascularization.
血管内皮生长因子(VEGF)可促进胎盘血管形成,而子痫前期和胎儿宫内生长受限(IUGR)时胎盘血管形成不足。VEGF的可溶性受体(sVEGFR-1),也称为可溶性fms样酪氨酸激酶-1,在胎盘中产生并降低VEGF活性。因此,sVEGFR-1升高可能导致子痫前期和IUGR的发生。
本研究旨在探讨孕早期发生子痫前期和IUGR的孕妇血清sVEGFR-1浓度。
这是一项病例对照研究。
本研究在三级转诊中心赫尔辛基大学中心医院(芬兰赫尔辛基)进行。
患者包括124名孕妇,其中49名发生子痫前期,16名分娩IUGR婴儿但无子痫前期,59名血压正常并分娩正常大小婴儿。在妊娠12 - 15周和16 - 20周时采集血清样本。
采用酶联免疫吸附测定法(ELISA)测定血清sVEGFR-1浓度。
随后发生子痫前期的孕妇在妊娠16 - 20周时sVEGFR-1浓度[中位数;四分位间距(IQR)]高于对照组(436和282 - 699 ng/升;P = 0.005)(296和184 - 508 ng/升)。若分别分析轻度(3